Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With PGTC Seizures

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With PGTC Seizures

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenobamate (Primary)
  • Indications Generalised seizures; Tonic-clonic epilepsy
  • Focus Registrational; Therapeutic Use
  • Sponsors SK Life Science

    • Most Recent Events

    • 29 Mar 2023 According to a SK biopharmaceuticals media release, company announced this phase 3 clinical trial plan (IND) for its innovative epilepsy new drug Cenobamate for adolescent generalized epilepsy, was approved by the Ministry of Food and Drug Safety.
    • 09 Feb 2023 This trial has been completed in Bulgaria.
    • 18 Jan 2023 According to a SK biopharmaceuticals media release, company submitted a phase 3 clinical trial plan (IND) for adolescent generalized epilepsy of Cenobamate, to the Ministry of Food and Drug Safety. It was announced on the 18th
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top